Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Amazon OTCs Likely A Worry For Retailers, A Remedy For Perrigo

Executive Summary

Amazon introduced Basic Care line of cough, cold, allergy and digestive treatment OTCs developed in a partnership with Perrigo. The range could be a major threat to store brand and private label OTCs, though success may depend on whether consumers wait for Amazon deliveries or shop at stores.


Related Content

Amazon Supplements, OTC Drugs Ride Lower Prices To Gains In Market Share
Amazon Expands Consumer Health With Advantage Of Cutting Prices
Amazon's Consumer Health Expansion Comes With Prices Sliced
Pricing Pressures 'Manageable' To P&G, But Threatening To Analysts
Private Label Nexium OTC Buoys Perrigo As Pricing Trims Rx Revenues
Perrigo Positioned To Prosper From Potential Amazon OTC Product Play
Perrigo Glows From Mucinex Private Label Plan, Starboard Plug
Perrigo CEO Takes Faith In Rx Generics Business To Exit Door With Him
Navigating Amazon: E-Commerce Giant Critical For OTC Drug Sales
Perrigo's Return To OTC Roots Restoring Investor Confidence


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts